



Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline...

Hatazawa, Keiko ; Tanaka, Hidekazu ; Nonaka, Akiko ; Takada, Hiroki ; Soga, Fumitaka ; Hatani, Yutaka ; Matsuzoe, Hiroki ; Shimoura, Hiroyuk...

(Citation)

Circulation Journal, 82(10):2566-2574

(Issue Date)

2018-09-25

(Resource Type)

journal article

(Version)

Version of Record

(Rights)

© 2018 THE JAPANESE CIRCULATION SOCIETY

(URL)

<https://hdl.handle.net/20.500.14094/90007476>



Baseline Global Longitudinal Strain as a Predictor of Left Ventricular Dysfunction and Hospitalization for Heart Failure of Patients With Malignant Lymphoma After Anthracycline Therapy

Keiko Hatazawa, MD; Hidekazu Tanaka, MD, PhD; Akiko Nonaka, MD, PhD;
Hiroki Takada, MD; Fumitaka Soga, MD; Yutaka Hatani, MD; Hiroki Matsuzoe, MD, PhD;
Hiroyuki Shimoura, MD, PhD; Junichi Ooka, MD, PhD; Hiroyuki Sano, MD, PhD;
Yasuhide Mochizuki, MD, PhD; Kensuke Matsumoto, MD, PhD; Ken-ichi Hirata, MD, PhD

Background: Our aim was to investigate the baseline clinical and echocardiographic parameters for predicting left ventricular (LV) dysfunction after anthracycline chemotherapy and heart failure (HF) hospitalization in a single cancer disease.

Methods and Results: We studied 73 patients with malignant lymphoma and preserved LV ejection fraction (LVEF). Echocardiography was performed before and after anthracycline chemotherapy. Global longitudinal strain (GLS) was determined from 3 standard apical views. LV dysfunction after anthracycline chemotherapy was defined according to the current definition of cancer therapeutics-related cardiac dysfunction. Long-term (50-month) unfavorable outcome was prespecified as hospitalization for HF. A total of 10 patients had LV dysfunction after anthracycline chemotherapy. Multivariate logistic regression analysis showed that baseline GLS was the only independent predictor of this dysfunction. Receiver-operating characteristic curve analysis identified the optimal GLS cutoff for predicting LV dysfunction after anthracycline chemotherapy as $\leq 19\%$ ($P=0.008$). Furthermore, the Kaplan-Meier curve indicated that fewer patients with GLS $>19\%$ were hospitalized for HF than among those with GLS $\leq 19\%$ (log-rank $P=0.02$). For sequential logistic models, a model based on baseline clinical variables ($\chi^2=2.9$) was improved by the addition of baseline LVEF ($\chi^2=9.0$; $P=0.01$), and further improved by the addition of baseline GLS ($\chi^2=13.1$, $P=0.04$).

Conclusions: Watchful observation or early therapeutic intervention with established cardioprotective medications may be necessary for patients with malignant lymphoma and preserved LVEF but with abnormal GLS.

Key Words: Echocardiography; Heart failure; Speckle tracking; Ventricular function

The mortality rate for patients with various types of cancer has recently decreased because of the diversity of anticancer drugs. However, cancer therapeutics-related cardiac dysfunction (CTRCD) has become a leading cause of morbidity and mortality in survivors,^{1,2} and the mortality rate for patients with CTRCD is as high as 60% by 2 years after treatment,³ caused by irreversible left ventricular (LV) myocardial changes due to anticancer drugs, such as myocyte loss, interstitial fibrosis leading to diminished LV contractility, reduced ventricular wall thickness, and progressive LV dilation. Anthracycline is an effective antineoplastic agent used for a wide spectrum of hematologic malignancies and solid tumors, but its most

Editorial p2477

serious adverse effect is progressive dose-dependent LV dysfunction followed by congestive heart failure (HF), even years after the treatment has been completed (Type I CTRCD).^{4–6} Therefore, early detection of LV myocardial damage caused by anthracycline could be important for predicting the possible occurrence of global LV dysfunction or to facilitate early treatment for Type I CTRCD.

Recently, there has been growing interest in early detection of CTRCD by means of global longitudinal strain (GLS) assessed 2D speckle-tracking strain, because it is a

Received March 20, 2018; revised manuscript received May 8, 2018; accepted May 23, 2018; released online July 6, 2018
Time for primary review: 29 days

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe (K. Hatazawa, H. Tanaka, H. Takada, F.S., Y.H., H.M., H. Shimoura, J.O., H. Sano, Y.M., K.M., K. Hirata); Division of Cardiology, Hyogo Cancer Center, Akashi (A.N.), Japan

Mailing address: Hidekazu Tanaka, MD, PhD, FACC, FASE, FAHA, FJCS, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
E-mail: tanakah@med.kobe-u.ac.jp

ISSN-1346-9843 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp




Figure 1. Example of a color-coded 2D display of the left ventricle (LV) and corresponding time-strain curves from 18 LV sites derived from 3 standard apical views for measurement of global longitudinal strain (GLS). GLS was determined as the average peak strain of 18 LV segments, and expressed as an absolute value.

more sensitive and robust parameter for detecting sub-clinical LV myocardial dysfunction than other conventional LV functional parameters such as LV ejection fraction (LVEF).⁷⁻¹³ In particular, early reduction in GLS during chemotherapy appears to be the most useful parameter for the prediction of CTRCD, although the utility of baseline GLS for predicting CTRCD and the development of HF during long-term follow-up remains unclear. Moreover, previous studies regarding CTRCD seem to be discrepant for reasons such as including different types of cancer for analysis. Our objective was therefore to investigate the baseline clinical and echocardiographic parameters, especially GLS, for predicting cardiotoxicity after undergoing anthracycline chemotherapy for patients with preserved LVEF and a single cancer disease.

Methods

Study Population

For this study 78 patients with malignant lymphoma who underwent anthracycline chemotherapy at Hyogo Cancer Center between March 2013 and April 2015 were retrospectively enrolled. Patients were considered eligible if they met the following inclusion criteria: (1) ≥ 18 years of age; and (2) preserved LV systolic dysfunction, defined as a LVEF $\geq 50\%$. We excluded patients with: (1) previous history of HF; (2) previous history or suspicion of coronary artery disease, which was carefully assessed by at least 3 senior cardiologists; (3) any known causes of cardiomyopathy; (4) uncontrolled hypertension $>180/100$ mmHg; (5) history of bone marrow transplantation; and (6) more than moderate valvular heart disease. Anemia was defined as a hemoglobin concentration <12 g/dL for women and <13 g/dL for men. We also excluded 5 patients (7%) from all subsequent analyses because of suboptimal images from

poor echocardiographic windows. Accordingly, the patient study group consisted of 73 patients with malignant lymphoma. This study was approved by the local ethics committees of Kobe University Hospital (No. 1807) and Hyogo Cancer Center (R-99).

Echocardiography

Echocardiographic studies were performed before and after the termination of anthracycline chemotherapy using a commercially available echocardiography system equipped with a 3.5-MHz transducer (iE33; Philips Medical Systems, Andover, MA, USA). Echocardiography after the termination of treatment with anthracycline was performed at the latest within 1 month of completing anthracycline chemotherapy. Digital routine grayscale 2D cine loops from 3 consecutive heart beats were obtained at end-expiratory apnea from standard parasternal and apical views and used for speckle-tracking strain analysis. Sector width was optimized to allow complete myocardial visualization while maximizing the frame rate. Standard echocardiographic measurements were obtained according to the current guidelines of the American Society of Echocardiography/European Association of Cardiovascular Imaging.¹⁴ Specifically, LV volumes and LVEF were assessed by modified biplane Simpson's rule using manual tracing of digital images. For patients with atrial fibrillation (AF), measurements of standard echocardiographic and speckle-tracking parameters were acquired as the average of ≥ 3 consecutive cardiac cycles.

LV Speckle-Tracking Analysis

All 2D speckle-tracking strain data were obtained with off-line analysis using dedicated software (QLAB version 10.0 software; Philips Medical Systems). Briefly, the first region of interest was manually traced with the point-and-

Table 1. Baseline Clinical and Echocardiographic Characteristics of the Patients With Malignant Lymphoma

	Patients (n=73)
Clinical data	
Age, years	64±15
Sex (M/F)	34/39
Body surface area, m ²	1.6±0.19
Systolic blood pressure, mmHg	117±14
Diastolic blood pressure, mmHg	69±10
Heart rate, beats/min	78±16
Atrial fibrillation, n (%)	10 (14)
Hypertension, n (%)	32 (44)
Diabetes mellitus, n (%)	14 (19)
Either hypertension or diabetes mellitus, n (%)	41 (56)
Dyslipidemia, n (%)	21 (29)
Anemia, n (%)	31 (43)
History of other cancer, n (%)	11 (15)
History of other chemotherapy, n (%)	3 (4)
History of radiation therapy, n (%)	2 (3)
Type of malignant lymphoma, n (%)	
Hodgkin lymphoma	2 (3)
Non-Hodgkin lymphoma	71 (97)
Ann Arbor stage, n (%)	
I	7 (9.6)
II	16 (22)
III	15 (20.5)
IV	35 (47.9)
Cumulative doxorubicin dose, mg/m ²	265±107
Distribution of cumulative doxorubicin dose (mg/m ²), n (%)	
0–99	8 (11)
100–199	13 (18)
200–299	20 (27)
300–399	29 (40)
400–499	3 (4)
>500	0 (0)
Medications	
CCB, n (%)	18 (41)
ACEI/ARB, n (%)	20 (27)
β-blocker, n (%)	5 (7)
Echocardiography	
LA diameter, cm	35±6
LA volume index, mL/m ²	26±11.9
LV end-diastolic diameter, mm	45±5
LV end-systolic diameter, mm	26±4
IVST, mm	9.5±1.4
PWT, mm	9.3±1.4
LV mass index, mL/m ²	89±18.5
LV end-diastolic volume, mL	71±18
LV end-systolic volume, mL	25±8
LVEF, %	65±5
E/A	0.9±0.3
e', cm/s	7.1±2.0
E/e'	9.6±2.8
Speckle-tracking data	
GLS, %	21.1±2.7

Values are mean±SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%). A, later diastolic wave velocity; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker; E, early diastolic wave velocity; e', early diastolic mitral annular velocity; GLS, global longitudinal strain; IVST, end-diastolic thickness of the interventricular septum; LVEF, left ventricular ejection fraction; PWT, end-diastolic thickness of the posterior wall.

Table 2. Comparison of Baseline Clinical and Echocardiographic Characteristics in Patients With and Without LV Dysfunction After Anthracycline Chemotherapy for Malignant Lymphoma

	Patients with LV dysfunction (n=10)	Patients without LV dysfunction (n=63)	P value
Clinical data			
Age, years	61±16	65±15	0.41
Sex (M/F)	5/5	29/34	0.82
Body surface area, m ²	1.6±0.16	1.6±0.19	0.94
Systolic blood pressure, mmHg	115±15	117±14	0.69
Diastolic blood pressure, mmHg	67±7	69±10	0.60
Atrial fibrillation, n (%)	3 (30)	7 (11)	0.11
Hypertension, n (%)	4 (40)	28 (44)	0.80
Diabetes mellitus, n (%)	4 (40)	17 (27)	0.41
Either hypertension or diabetes mellitus, n (%)	5 (50)	36 (57)	0.68
Dyslipidemia, n (%)	4 (40)	17 (27)	0.41
Anemia, n (%)	6 (60)	25 (40)	0.23
History of other cancer, n (%)	2 (20)	9 (35)	0.64
History of other chemotherapy, n (%)	1 (10)	2 (3)	0.32
History of radiation therapy, n (%)	1 (10)	1 (1.5)	0.13
Ann Arbor stage, n (%)			
I	1 (10)	6 (10)	0.96
II	0 (0)	16 (25)	0.07
III	1 (10)	14 (22)	0.38
IV	8 (80)	27 (43)	0.03
Cumulative doxorubicin dose, mg/m ²	279±114	263±107	0.70
Distribution of cumulative doxorubicin dose (mg/m ²), n (%)			
0–99	0 (0)	8 (13)	0.24
100–199	3 (30)	10 (16)	0.28
200–299	2 (20)	18 (29)	0.58
300–399	4 (40)	25 (40)	0.99
400–499	1 (10)	2 (3)	0.32
>500	0 (0)	0 (0)	1.0
Medications			
CCB, n (%)	1 (10)	17 (27)	0.25
ACEI/ARB, n (%)	2 (20)	18 (29)	0.58
β-blocker, n (%)	1 (10)	4 (6)	0.68
Echocardiography			
LA diameter, cm	35±9	35±6	0.78
LA volume index, mL/m ²	32±15.3	25±11	0.06
LV end-diastolic diameter, mm	46±6	45±5	0.57
LV end-systolic diameter, mm	27±5	26±4	0.33
IVST, mm	9.8±0.9	9.4±1.5	0.43
PWT, mm	9.6±1.1	9.2±1.5	0.43
LV mass index, mL/m ²	96±19.5	88±18.2	0.19
LV end-diastolic volume, mL	85±19	69±18	0.01
LV end-systolic volume, mL	33±9	24±7	<0.001
LVEF, %	60±7	65±5	<0.01
E/A	0.8±0.2	0.9±0.3	0.31
e', cm/s	6.8±1.4	7.1±2.1	0.60
E/e'	9.9±2.6	9.6±2.8	0.73
Speckle-tracking data			
GLS, %	18.5±3.4	21.6±2.4	<0.001


Abbreviations as in Table 1.

click approach on the LV endocardium at the end-systole phase. The second larger region of interest was then generated outside and carefully adjusted near the epicardium. Finally, 6 strain segments and corresponding time-strain curves were generated. The onset point of the QRS com-

plex was used as a reference for LV strain analysis. GLS was then determined as the peak strain averaged from the 3 standard apical views as expressed as an absolute value in accordance with current guidelines (Figure 1).¹⁴

Table 3. Univariate and Multivariate Logistic Regression Analyses						
Variables	Univariate analysis			Multivariate analysis		
	OR	95% CI	P value	OR	95% CI	P value
Clinical variables						
Age (per 5 years)	0.983	0.943–1.024	0.411			
Sex (female)	1.172	0.309–4.455	0.815			
Cumulative doxorubicin dose	1.002	0.995–1.001	0.651			
Hypertension	0.833	0.214–3.245	0.793			
Diabetes mellitus	1.804	0.453–7.185	0.403			
Atrial fibrillation	3.429	0.717–16.38	0.123			
History of radiation therapy	6.889	0.395–120.1	0.186			
Baseline echocardiographic variables						
Left atrial dimension	1.015	0.918–1.122	0.780			
LVEF (per 5%)	0.832	0.723–0.957	0.019			
E/e' (per 5 unit)	1.044	0.825–1.321	0.723			
GLS	0.652	0.489–0.869	0.004	0.652	0.489–0.869	0.004

CI, confidence interval; OR, odds ratio. Other abbreviations as in Table 1.



Definitions of LV Dysfunction After Anthracycline Chemotherapy and Long-Term Outcome Analysis
After the cessation of anthracycline chemotherapy, echocardiography was performed for all patients. According to the current definition of CTRCD, LV dysfunction after anthracycline chemotherapy was defined as the presence of (1) an absolute decrease in LVEF ≥10% to a final value <53% in asymptomatic patients or (2) an absolute decrease in LVEF ≥5% to a final value <53% in symptomatic patients.^{12,15} Long-term unfavorable outcome events were prespecified as the primary endpoint of hospitalization for deteriorating HF. For long-term follow-up, all 73 patients were tracked for 50 months.



Statistical Analysis
Continuous variables are expressed as mean values ± SD or

percentages, and categorical data are summarized as frequencies and percentages. The parameters of the 2 subgroups were compared by unpaired t test, and the paired t test was used for comparison of continuous variables. Proportional differences were evaluated with Fisher’s exact test or χ^2 test as appropriate. Optimal cutoff values for the association of baseline GLS with LV dysfunction after anthracycline chemotherapy were determined on the basis of receiver-operator characteristics (ROC) curve analysis. Event-free survival curves were determined with the Kaplan-Meier method and cumulative event rates were compared by log-rank test. The initial univariate logistic regression analysis to identify univariate predictors of LV dysfunction was followed by a multivariate logistic regression model using stepwise selection, with P levels for entry set at <0.1. Sequential logistic models were constructed to determine any incremental benefits of baseline GLS compared with clinical and conventional echocardiographic variables. A statistically significant increase in the global log-likelihood χ^2 of the model was defined as an increment in predictive value. No multicollinearity was shown among parameters in this study. The intraclass correlation coefficient was then used to determine inter- and intraobserver reproducibilities for speckle-tracking parameters from 20 randomly selected patients using an identical cine-loop for each view. For all steps, P<0.05 was considered statistically significant. All analyses were performed with commercially available software (MedCalc software version 15.11.4; MedCalc Software, Mariakerke, Belgium).

Results

Baseline Characteristics
The baseline clinical and echocardiographic characteristics of the 73 patients with malignant lymphoma are summarized in **Table 1**. Their mean age was 64±15 years, 34 were female, LVEF was 65±5%, and the cumulative anthracycline dose was 265±107 mg/m².

Predictors of LV Dysfunction After Anthracycline Chemotherapy
Of the 73 patients for whom follow-up echocardiographic data were available, 10 (14%) were diagnosed with LV



dysfunction according to the predefined criteria, and the remaining 63 patients (86%) were classified as having non-LV dysfunction, all after anthracycline chemotherapy (Table 2). Baseline clinical and echocardiographic parameters were similar except that patients with LV dysfunction

after anthracycline chemotherapy were more likely to have a larger LV volume, and lower LVEF and GLS. Moreover, the prevalence of taking angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), or β -blockers was similar between groups. Results of uni-

Table 4. Comparison of Baseline Clinical and Echocardiographic Characteristics in Patients With GLS >19% or ≤19%

	Patients with GLS >19% (n=59)	Patients with GLS ≤19% (n=14)	P value
Clinical data			
Age, years	65±15	62±16	0.45
Sex (M/F)	29/30	5/9	0.37
Body surface area, m ²	1.59±0.2	1.66±0.2	0.21
Atrial fibrillation, n (%)	6 (10)	4 (29)	0.07
Hypertension, n (%)	24 (41)	8 (57)	0.27
Diabetes mellitus, n (%)	16 (27)	5 (36)	0.53
Either hypertension or diabetes mellitus, n (%)	32 (54)	9 (64)	0.50
Dyslipidemia, n (%)	15 (25)	6 (43)	0.20
History of another cancer, n (%)	7 (12)	4 (29)	0.12
Previous radiation therapy, n (%)	1 (2)	1 (7)	0.27
Cumulative doxorubicin dose, mg/m ²	266±103	260±125	0.85
Medications			
CCB, n (%)	14 (24)	4 (29)	0.71
ACEI/ARB, n (%)	17 (29)	3 (21)	0.58
β-blocker, n (%)	4 (6)	1 (7)	0.96
Echocardiography			
LV end-diastolic diameter, mm	45.4±4.5	44.7±5.2	0.60
LV end-systolic diameter, mm	26.0±4.2	25.7±4.6	0.79
IVST, mm	9.3±1.3	10.1±1.7	0.08
PWT, mm	9.1±1.4	10±1.4	0.03
Relative wall thickness, mm	0.41±0.1	0.46±0.1	0.03
LV end-diastolic volume, mL	71±19	73±19	0.66
LV end-systolic volume, mL	24±7.3	30±9.8	<0.001
Left atrial diameter, mm	35±5.7	36±9.7	0.37
LVEF, %	66±4.5	60±5.4	<0.001
LVSF, mL	46±12	43±10	0.33
E/A	0.9±0.3	0.9±0.2	0.59
e', cm/s	7.1±2.1	6.8±1.9	0.55
E/e'	9.3±2.6	11.0±3.3	0.04

Abbreviations as in Table 1.

variate and multivariate analyses using logistic regression analysis for LV dysfunction after anthracycline chemotherapy are shown in **Table 3**. An important finding from the multivariate logistic regression analysis was that GLS was the only independent predictor of LV dysfunction after anthracycline chemotherapy (odds ratio: 0.652; 95% confidence interval (CI): 0.489–0.869; $P=0.004$). In addition, ROC curve analysis identified the optimal GLS cutoff for predicting LV dysfunction after anthracycline chemotherapy as ≤19%, with a sensitivity of 60%, specificity of 87%, and area under the curve of 0.77 ($P=0.008$, **Figure 2**).

The incremental benefit using sequential logistic models for the prediction of LV dysfunction after anthracycline chemotherapy is shown in **Figure 3**. A model based on baseline clinical variables including age, sex, previous radiation therapy, posterior wall thickness, relative wall thickness, and cumulative anthracycline dose ($\chi^2=2.9$) was improved by including conventional baseline echocardiographic variables, including LVEF ($\chi^2=9.0$; $P=0.01$), and further improved by the addition of baseline GLS ($\chi^2=13.1$, $P=0.04$).

Association of GLS With Long-Term Outcome

The primary endpoint of hospitalization for HF was

recorded for 5 of the 73 patients (6.8%). The Kaplan-Meier curve indicated that fewer patients with GLS >19% were hospitalized for HF than among those with GLS ≤19% after anthracycline chemotherapy (log-rank $P=0.02$; **Figure 4**). Some patients were taking ACEI, ARB, or β-blockers for hypertension or other reasons (**Table 1**), but none of medications affected the long-term outcomes.

Comparisons of Baseline Parameters of Patients With GLS >19% and GLS ≤19%

Because GLS ≤19% was associated with LV dysfunction after anthracycline chemotherapy and hospitalization for HF during long-term follow-up, patients were divided into 2 groups using a cutoff value of GLS=19% for a comparison of patient characteristics (**Table 4**). It was noteworthy that patients with GLS ≤19% were more likely to have LV hypertrophy (LVH: end-diastolic thickness of the interventricular septum (IVS): 10.1±1.7 mm vs. 9.3±1.3 mm, $P=0.08$, end-diastolic thickness of the posterior wall: 10±1.4 mm vs. 9.1±1.4 mm, $P=0.03$, relative wall thickness: 0.41±0.1 mm vs. 0.46±0.1 mm, $P=0.03$), and higher early diastolic wave velocity and early diastolic mitral annular velocity ratio (E/e') (11.0±3.3 vs. 9.3±2.6, $P=0.04$) than those with GLS >19%. Moreover, patients with GLS ≤19% tended to have

higher prevalence of AF than those with GLS $>19\%$, but not statistically significant (29% vs. 10% , $P=0.07$).

Reproducibility

The intraclass correlation coefficient for interobserver reproducibility of GLS was 0.979 (95% CI: 0.946–0.9917), and the intraclass correlation coefficient for intraobserver reproducibility of GLS was 0.926 (95% CI: 0.8122–0.9706).

Discussion

We found that baseline GLS was the only independent predictor of LV dysfunction after anthracycline chemotherapy for patients with malignant lymphoma and preserved LVEF. In addition, baseline GLS $\leq 19\%$ was associated with reduced LVEF after anthracycline chemotherapy and hospitalization for HF during long-term follow-up. The lower baseline GLS also yielded significant increments in predictive value compared with conventional clinical echocardiographic variables. This is the first study to demonstrate an association of LV myocardial function before anthracycline chemotherapy with LV systolic dysfunction after anthracycline chemotherapy and hospitalization for HF during long-term follow-up of a single cancer disease.

Association of LV Longitudinal Myocardial Dysfunction With CTRCD

LVEF is the most common parameter used to assess LV systolic function, and the usefulness of LVEF to detect CTRCD has been previously reported. However, LVEF is an inaccurate parameter of CTRCD because it is insensitive to early changes in cardiac function during a potentially cardiotoxic treatment. Moreover, it is not an accurate predictor of HF of patients who receive anthracycline therapy, because the heart has plenty of reserves and LVEF does not start to deteriorate until the later stages of HF.^{5,16,17} Interest has thus been on the possibility of measuring a more sensitive and robust noninvasive, simple parameter for LV function. In the early stages of HF, or in the case of subclinical LV dysfunction, strain imaging by means of echocardiography can be of considerable help in both diagnostic evaluation and determining prognosis. In this respect, the ability of GLS to predict both subclinical LV dysfunction and cardiovascular outcome may be superior to that of LVEF in a number of cardiac disorders.^{18,19} In fact, some recent investigators have used GLS for the identification of anthracycline-induced early LV longitudinal myocardial dysfunction after chemotherapy.^{7,8,10,20,21} A systematic review of 1,504 patients during or after cancer chemotherapy showed that early changes in GLS were the best measure for predicting cardiotoxicity.¹⁰ Specifically, a 10–15% early reduction in GLS during chemotherapy appears to be the most useful parameter for predicting cardiotoxicity, defined as a reduction in LVEF or HF. The LV wall is not homogeneous and has 3 layers of fibers, with the endocardial layer often the first to be affected by various diseases. Because this layer is mainly responsible for long-axis contraction, a reduction in longitudinal function has been found to be an early and accurate indicator of LV dysfunction in patients with high susceptibility to CTRCD, as well as ischemia, fibrosis, and hypertrophy.^{8,10,12,13,22,23} Much earlier, Milei et al used anthracycline-treated rabbits to provide pathologic evidence that anthracycline cardiotoxicity caused progressive vacuoliza-

tion of the myocardial fibers, leading to severe myocytolysis in the LV subendocardium and the interventricular septum.²³ Our group also previously reported that global area strain detected by 3D speckle-tracking imaging, which can quantify the endocardial area change ratio when it is coupled with the factors of both endocardial longitudinal and circumferential strain obtained from all LV segments, was the only parameter independently associated with the cumulative dose in 55 patients with preserved LVEF after undergoing anthracycline chemotherapy.²⁴

Clinical Implications

The association of early LV longitudinal myocardial dysfunction with CTRCD after various types of chemotherapy may have been verified, but the characteristics of LV longitudinal myocardial function before anthracycline chemotherapy in a specific, individual type of cancer disease remain indeterminate. During the long-term follow-up in our study, we found an association of reduced LVEF after anthracycline therapy and with hospitalization for HF in patients with malignant lymphoma and baseline GLS $\leq 19\%$. The lower baseline GLS also yielded significant increments in predictive value compared with conventional clinical echocardiographic variables. The cutoff value of GLS of 19% used in our study was close to both the normal GLS value of 20% in the guideline of the American Society of Echocardiography¹⁴ and the mean normal value of 19.7% reported in a meta-analysis.²⁵ CTRCD may present initially as asymptomatic LV dysfunction and ultimately as symptomatic HF, which can occur even decades after the discontinuation of chemotherapy. Furthermore, Type I CTRCD is believed to be refractory to conventional pharmacological therapy and is associated with a poor prognosis.^{4–6} Therefore, early detection of Type I CTRCD, preferably before undergoing anthracycline therapy, is crucial, as it will enable early application of preventive strategies with established cardioprotective medications such as ACEI, ARB or β -blockers for patients with malignant lymphoma and preserved LVEF, but an abnormal baseline GLS. In addition, patients with abnormal baseline GLS are more likely than those with a normal GLS to have LVH, AF, and higher E/e', which are comorbidities significantly associated with LV longitudinal myocardial dysfunction but preserved LVEF.²⁶ Moreover, LVH, AF, and LV diastolic dysfunction are also considered to be risk factors for the development of CTRCD.^{9,26,27} Thus, watchful observation after anthracycline chemotherapy or after early preventive strategies with established cardioprotective medications but before anthracycline chemotherapy is recommended for patients with malignant lymphoma and preserved LVEF who have such comorbidities.

Study Limitations

This study had a relatively small number of patients in a retrospective single-center study, so further prospective studies with larger patient populations will be needed to validate our findings. The prevalence of Ann Arbor stage IV in patients with LV dysfunction was significantly higher than in patients without LV dysfunction (80% vs. 43%). Although the association of cancer cachexia with the development of LV dysfunction after anthracycline therapy remains uncertain, its effect may be undeniable in this study. Finally, this study enrolled relatively elderly patients (64 ± 15 years old), but anthracycline is widely used for treatment in various age groups, including young patients.

Thus, it remains unclear if the cutoff value of GLS $\leq 19\%$ can be applied to younger patients.

Conclusions

Baseline GLS was found to be associated with LV dysfunction after anthracycline chemotherapy and the development of HF during long-term follow-up of patients with malignant lymphoma and preserved LVEF. Because anthracycline causes changes in LV performance over time, watchful observation or early therapeutic intervention with established cardioprotective medications may be necessary for such patients with preserved LVEF but abnormal GLS.

References

1. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007; **99**: 365–375.
2. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. *J Clin Oncol* 2005; **23**: 8597–8605.
3. Felker GM, Thompson RE, Hare JM, Hruban RH, Cimetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000; **342**: 1077–1084.
4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozenzweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 1979; **91**: 710–717.
5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer* 2003; **97**: 2869–2879.
6. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. *Circulation* 2004; **109**: 3122–3131.
7. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. *Eur Heart J Cardiovasc Imaging* 2014; **15**: 324–331.
8. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. *J Am Soc Echocardiogr* 2013; **26**: 493–498.
9. Negishi T, Negishi K. Echocardiographic evaluation of cardiac function after cancer chemotherapy. *J Echocardiogr* 2018; **16**: 20–27.
10. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. *J Am Coll Cardiol* 2014; **63**: 2751–2768.
11. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2014; **15**: 1063–1093.
12. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2014; **27**: 911–939.
13. Rhea IB, Uppuluri S, Sawada S, Schneider BP, Feigenbaum H. Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients. *J Am Soc Echocardiogr* 2015; **28**: 667–673.
14. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015; **28**: 1–39.e14.
15. Martin M, Esteve FJ, Alba E, Khandheria B, Perez-Isla L, Garcia-Saenz JA, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. *Oncologist* 2009; **14**: 1–11.
16. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. *Ann Oncol* 2002; **13**: 699–709.
17. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? *J Clin Oncol* 2008; **26**: 1201–1203.
18. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: A systematic review and meta-analysis of global longitudinal strain and ejection fraction. *Heart* 2014; **100**: 1673–1680.
19. Gorcsan J 3rd, Tanaka H. Echocardiographic assessment of myocardial strain. *J Am Coll Cardiol* 2011; **58**: 1401–1413.
20. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study. *Heart* 2010; **96**: 701–707.
21. Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): A prospective study. *Eur Heart J Cardiovasc Imaging* 2013; **14**: 562–569.
22. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circ Cardiovasc Imaging* 2012; **5**: 596–603.
23. Milei J, Boveris A, Llesuy S, Molina HA, Storino R, Ortega D, et al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. *Am Heart J* 1986; **111**: 95–102.
24. Miyoshi T, Tanaka H, Kaneko A, Tatsumi K, Matsumoto K, Minami H, et al. Left ventricular endocardial dysfunction in patients with preserved ejection fraction after receiving anthracycline. *Echocardiography* 2014; **31**: 848–857.
25. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: A meta-analysis. *J Am Soc Echocardiogr* 2013; **26**: 185–191.
26. Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: How useful is it in clinical decision making? *Eur Heart J* 2016; **37**: 1196–1207.
27. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016; **37**: 2768–2801.